Inflammasome Therapeutics’ Kamuvudines May Be Answer To Preventing Blindness In Aging Population
NEWTON, Mass.–(BUSINESS WIRE)–Inflammasome Therapeutics (https://www.inflam.com), a private company developing therapies for prevalent, degenerative diseases, reported newly published research continues to confirm the potential of the company’s proprietary Kamuvudines, to be…